Inhibition of MIF Bioactivity by Rational Design of Pharmacological Inhibitors of MIF Tautomerase Activity
Angeles Dios, Yousef Al‐Abed, Jodi B. Lubetsky(Yale University), Hong Liao(China Pharmaceutical University), KerryAnn O'Connor(Yale University), Elias Lolis(Yale Cancer Center), Bayan Aljabari, Christine N. Metz(Northwell Health), Peter D. Senter(North Carolina Central University), Kirk R. Manogue, Robert A. Mitchell(University of Louisville), Richard Bucala(Yale University), David J.E. Callaway(Yale University)
Cited by 125
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
MIF Signal Transduction Initiated by Binding to CD74
|The Journal of Experimental Medicine|2003|1.1k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k